Conagen develops high-purity non-GMO sulforaphane by bioconversion
Commercial production is underway for 2023.
Bedford, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Expanding on its portfolio of innovative nutritional products through biotechnology, Conagen, announced the development of its 99% high-purity sulforaphane. Made by a proprietary bioconversion technology, the company plans to begin the commercialization path in 2023. Conagen’s bioconversion methods enable the production of sustainable products from many naturally occurring compounds regardless of rarity or small quantities occurring in nature.
“As a supplement product, Conagen’s high-purity sulforaphane is appealing to consumers as the levels found in raw vegetables are too low to realize many of its promising health benefits,” said Casey Lippmeier, Ph.D., senior vice president of innovation. “We’re looking forward to expanding the nutritional market by commercializing sulforaphane in 2023.”
Sulforaphane has been associated with supporting health benefits against cancer, diabetes, digestion, and heart disease and promoting cognition. With biotechnology and biomanufacturing advancements, much like Conagen’s bioconversion technology, more nutritional offerings are produced at a high-quality and global scale.
Sulforaphane is found in cruciferous vegetables such as arugula, bok choy, broccoli, Brussels sprouts, cabbage, kale, radish, and more. In these vegetables, the inactive form of glucoraphanin belongs to the glucosinolate family of plant compounds. The sulfur-rich sulforaphane is activated only when vegetables are chewed or chopped to release myrosinase, a class of enzymes that play a role in the defense response of plants.
“Through Conagen’s bioconversion technology, we’re uncovering the great potential in sulforaphane as a powerful active health ingredient for consumers who are personalizing nutrition to support health functions,” said Lippmeier. “We can make safe and high-quality nutritional ingredients from natural sources and offer it at a global-scale cost-competitively so that brands may pass on the good health and savings to their consumers.”
Conagen’s sulforaphane is ideal for non-GMO supplement solutions to formulate products with a sustainable and natural consumer appeal. More research is emerging for understanding the optimistic effects on multiple health functions. As one example of many, biotechnology and biomanufacturing will continue to harness the power of biology and nature to develop and deliver solutions for better nutrition, health, and wellness. Conagen is expanding its sustainable, nutritional products portfolio to better humankind and the planet.
Conagen is making the impossible possible. Our scientists and engineers use modern synthetic biology tools to program micro-organisms and enzymes on a molecular level to produce high-quality, sustainable, natural products manufactured worldwide via precision fermentation and bioconversion. We focus on the bioproduction of high-value ingredients for food, nutrition, flavors and fragrances, pharmaceuticals, and renewable materials.
- Sulforaphane is found in cruciferous vegetables
- Sulforaphane has been associated with supporting health benefits.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
RULE 2.9 ANNOUNCEMENT1.2.2023 16:40:00 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE 1 FEBRUARY 2023 PAYPOINT PLC ("PAYPOINT") RULE 2.9 ANNOUNCEMENT In accordance with Rule 2.9 of The City Code on Takeovers and Mergers, the Company confirms that, as at the date and time of this announcement, its issued share capital consists of 68,986,938 ordinary shares of 1/3 pence each, which carry voting rights of one vote per share. The Company does not hold any ordinary shares in treasury. The International Securities Identification Number for the Company's ordinary shares is GB00B02QND93. Enquiries: PayPoint plc Brian McLelland, Company Secretary +44(0)7721211100
Treasury Bond Auction Announcement - RIKB 26 1015 - RIKS 37 01151.2.2023 16:31:00 CET | Press release
SeriesRIKB 26 1015RIKS 37 0115ISINIS0000034874IS0000033793Maturity Date10/15/202601/15/2037Auction Date02/03/202302/03/2023Settlement Date02/08/202302/08/202310% addition02/07/202302/07/2023 On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%. Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government Debt Management website. For additional information please contact Oddgeir Gunnarsson, Government Debt Management, at +354 569 9635.
The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions1.2.2023 15:40:00 CET | Press release
Talenom Plc, Stock Exchange Release 1 February 2023 at 16:40 EET The Board of Directors of Talenom Plc has decided on a directed share issue as part of acquisitions Talenom Plc announced two acquisitions on 1 February 2023. Part of the purchase prices will be paid in cash and part with new shares of Talenom Plc subscribed in a directed share issue. The transaction prices are not disclosed. As part of the transactions, Talenom has decided to issue 50,825 new shares in a directed share issue for the sellers of the acquisition targets, i.e., BKF Asesores, S.L. and R2 Redovisning Ab. The subscription date for the shares is 1 February 2023. The number of new shares to be issued corresponds with some 0.11 percent of all Talenom Plc's shares prior to the share issue. After the registration of the new shares the total number of shares in Talenom Plc is 44,986,213 shares. The new shares will carry shareholder rights as of their registration day, estimated on 3 February 2023. The shares issued i
Talenom expands its operations in Spain by acquiring an accounting firm in Madrid1.2.2023 15:35:00 CET | Press release
Talenom Plc, press release 1 February 2023 at 16:35 EET Talenom expands its operations in Spain by acquiring an accounting firm in Madrid Talenom Plc has agreed to acquire the entire share capital of BKF Asesores, S.L., an accounting firm operating in Madrid, Spain. The acquired business will be transferred to Talenom on 1 February 2023. BKF Asesores, S.L. provides accounting, payroll and advisory services mainly to SMEs. The net sales transferred to Talenom from the acquired business is some EUR 0.7 million annually. The company employs a total of nine persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 85
Talenom acquires the Swedish accounting firm R2 Redovisning Ab1.2.2023 15:30:00 CET | Press release
Talenom Plc, press release 1 February 2023 16:30 EET Talenom acquires the Swedish accounting firm R2 Redovisning Ab Talenom Plc has agreed to acquire the entire share capital of R2 Redovisning Ab. The acquired business will be transferred to Talenom on 1 February 2023. R2 Redovisning Ab operates in Gothenburgh and Kungsbacka. The company provides accounting, payroll and advisory services mainly to SMEs. The yearly net sales transferred to Talenom from the acquired business is approximately EUR 0.7 million. The company employs a total of seven persons who will continue to work for Talenom. In the short term, the acquisition will not have any significant impact on Talenom’s financial position or future outlook. Talenom combines software development with expertise in the accounting industry in a unique way. The aim of the company is to grow both organically and through acquisitions in Finland and in Europe. Further information: Otto-Pekka Huhtala CEO, Talenom Plc +358 40 703 8554 otto-pek